Skip to main content
Harvey Friedman, MD, Infectious Disease, Philadelphia, PA, Hospital of the University of Pennsylvania

HarveyMFriedmanMD

Infectious Disease Philadelphia, PA

Professor of Medicine, University Pennsylvania

Dr. Friedman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Friedman's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Infectious Disease, 1973 - 1975
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1973 - 1975
  • McGill University Faculty of Medicine
    McGill University Faculty of MedicineClass of 1969

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1973 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1986

Clinical Trials

Publications & Presentations

PubMed

Other

Press Mentions

  • Race to Develop mRNA Flu Vaccines Will Contend with a Longer Review Than Covid-19
    Race to Develop mRNA Flu Vaccines Will Contend with a Longer Review Than Covid-19August 11th, 2021
  • After Covid-19, mRNA Technology Aims to Revolutionise the Flu Shot
    After Covid-19, mRNA Technology Aims to Revolutionise the Flu ShotAugust 10th, 2021
  • How mRNA Vaccines Could Prevent or Eliminate Infectious Diseases Beyond COVID-19
    How mRNA Vaccines Could Prevent or Eliminate Infectious Diseases Beyond COVID-19June 15th, 2021
  • Join now to see all

Grant Support

  • InternationalNational Institute Of Allergy And Infectious Diseases2009–2011
  • Blocking Immune Evasion As A Novel HSV Vaccine ApproachNational Heart, Lung, And Blood Institute2008–2010
  • Postdoctoral Training Grant In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2001–2010
  • Herpes Simplex Virus FC ReceptorNational Institute Of Allergy And Infectious Diseases1992–2009
  • Blocking Immune Evasion As A Nevel HSV Vaccine ApproachNational Heart, Lung, And Blood Institute2007
  • Virus &Immune Injury To Vessel Wall CellsNational Heart, Lung, And Blood Institute1991–2006
  • Protease Inhibitor-Sparing Regimens For The Initial Treatment Of HIV SubjectsNational Center For Research Resources2005
  • Cryopreservation Evaluation In HIV SubjectsNational Center For Research Resources2005
  • Comparison Of Lopinavir/Ritonavir PLUS Efavirenz Versus Lopinavir/RitonavirNational Center For Research Resources2005
  • Beta-D-2, Dapd, Versus DAPD PLUS MMF In Treatment HIV SubjectsNational Center For Research Resources2005
  • ACTG A5116: Simplified Regimens Regimen VS A Nucleoside-Sparing RegimenNational Center For Research Resources2005
  • ACTG A5001: Adult AIDS Clinical Trials Group Longitudinal Linked TrialsNational Center For Research Resources2005
  • Herpes Simplex Virus Immune Evasion In HIV SubjectsNational Institute Of Dental &Craniofacial Research2001–2005
  • Lopinavir/Ritonavir PLUS Efavirenz Versus Lopinavir/RitNational Center For Research Resources2004
  • HIV Infected Subjects WHO Have 200 HIV-1 RNA Copies/MlNational Center For Research Resources2004
  • Beta-D-2,6-Diaminopurine Dioxolane Versus DAPD PLUS Mycophenolate MofetilNational Center For Research Resources2004
  • Adult AIDS Clinical Trials Group Longitudinal Linked Randomized TrialsNational Center For Research Resources2004
  • 3 Protease Inhibitor-Sparing Regimens For The Initial Treatment Of HIV InfectionNational Center For Research Resources2004
  • Sb-265805 Compared With Cefuroxime Axetil In Acute SinusNational Center For Research Resources2000–2002
  • Core--Clinical FacilityNational Institute Of Allergy And Infectious Diseases1999–2002
  • ACTG 892: Effect Of Highly Active Antiretroviral Therapy On Lean BodyNational Center For Research Resources1999–2002
  • ACTG 383:Subjects W/ Hepatitis C Virus &Human Immunodeficiency VirusNational Center For Research Resources1999–2002
  • HSV 007--Skbs HSV Vaccine To Prevent Genital Herpes In Healthy SubjectsNational Center For Research Resources1998–2002
  • ACTG 360-- Prospective Study Of HIV Wrt CMV Burden Endorgan DiseaseNational Center For Research Resources1998–2002
  • Hsv107--Herpes Simplex Vaccine (GD2T) In HSV + Or - Consorts With Genital HerpesNational Center For Research Resources1997–2002
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–2002
  • HSV 16--Herpes Simplex Candidate Vaccine With MPL In HSV PTS W/O Genital HerpesNational Center For Research Resources1997–2000
  • Virus And Immune Injury To Vessel Wall CellsNational Heart, Lung, And Blood Institute1987–2000
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Herpes Simplex Virus FC ReceptorNational Institute Of Allergy And Infectious Diseases1997
  • HSV 007--Skbs HSV Vaccine To Prevent Genital Herpes In Healthy SubjectsaNational Center For Research Resources1997
  • Actg229--Ro31 8959 PLUS Zidovudine VS Zidovudine PLUS DDCNational Center For Research Resources1997
  • ACTG 244--Condon 215 Mutation In Zvd Monotherapy/Maintenance TherpyNational Center For Research Resources1997
  • ZDV VS ZDV + Ddl VS ZDV + Ddl + NVP In Asymptomatic HIV PatientsNational Center For Research Resources1996
  • Actg229--Ro31-8959 PLUS Zidovudine VS Zidovudine PLUS ZalcitabineNational Center For Research Resources1996
  • AIDS Clinical TrialNational Institute Of Allergy And Infectious Diseases1994–1995
  • AIDS Clinical Trial UnitNational Institute Of Allergy And Infectious Diseases1992–1993
  • Steroid Regulation Of HSV 1 Glycoprotein C ExpressionFogarty International Center1986
  • Virus And Immune Injury To Vessel Wall CellsNational Heart, Lung, And Blood Institute1985–1986

Hospital Affiliations